Clinical trial
A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B
NCT03576066 is registered in ClinicalTrials.gov with Assembly Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B
- Lead sponsor
- Assembly Biosciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 11, 2018
- Completion date
- July 5, 2019
- Enrollment
- 73 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b